# BPC-157 Dosage in Research: How Doses Are Expressed, Routes, and Half-Life > How BPC-157 dosage appears in the research literature: per-kilogram animal-model figures, the routes studied, a half-life under 30 minutes, and why no validated human dosing protocol exists. Research context, not human guidance. Animal-model figures, the routes studied, and the short half-life — read as research data, never as human dosing guidance. ## How BPC-157 Doses Are Expressed in Research BPC-157 dosage in the research literature is written per unit of body weight, not as a human prescription. Rodent studies commonly express dose per body weight — frequently around 10 µg/kg and 10 ng/kg, and as low as 10 pg in some tendon work [1]. These are animal-model figures, reported to describe what was administered to which species, not guidance for people. The per-kilogram convention is the first thing to understand. A figure like "10 µg/kg" scales the amount to the animal's mass, so it cannot be read off as a fixed human dose; it is a way of standardizing across rats of different sizes. The gastric-ulcer cytoprotection work, for instance, used 400 ng/kg and 800 ng/kg in rats [4]. Notice the units — nanograms and micrograms per kilogram — which are far smaller than the milligram figures people often assume. The human pilot data are minimal and route-specific. A two-person intravenous safety pilot used 10 mg then 20 mg by infusion [10], and an interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy [7]. Those are total fixed amounts in tiny feasibility studies, not validated regimens. Reading any of these figures correctly means reading them as study parameters — a record of [how research doses are expressed](/dosage), not a protocol to follow. This site reports the numbers so the literature is legible; it does not convert them into instructions. ## Routes of administration studied BPC-157 has been studied across a wide range of routes, and the route often matters to the result. The most common in rodent work is intraperitoneal injection [1]. Others include intramuscular, intragastric/peroral, and local or intra-lesional delivery [4]. The human pilots add intravenous [10], intravesical [7], and intra-articular [6] routes. The 2004 gastric-ulcer study found intramuscular delivery outperformed intragastric, a reminder that route is a variable, not a footnote [4]. None of these establishes a validated human administration protocol. ## Half-life and what it implies BPC-157's elimination half-life is reported as under 30 minutes in the 2022 rat-and-dog pharmacokinetic study, after intravenous and intramuscular dosing [2]. Intramuscular bioavailability was roughly 14-19% in rats and 45-51% in dogs [2]. A short half-life means systemic exposure from any single dose is brief, and the measurable tissue changes seen in animal models accrue over repeated dosing across days rather than from one administration [2]. That is a pharmacokinetic observation about animal data, not a dosing schedule. The fuller account of [BPC-157 half-life and pharmacokinetics](/research) sits on the research page. ## Stability, reconstitution, and storage in research handling Because BPC-157 is reported to be stable in gastric juice, it is described as a *stable gastric pentadecapeptide* [2]. Research handling typically involves a lyophilized (freeze-dried) peptide reconstituted in a diluent such as bacteriostatic water [5]. These reconstitution and storage practices are research-context conventions, not validated clinical protocols, and formal human oral pharmacokinetics remain unestablished [2]. ## Why no validated human dosing exists There is no validated human BPC-157 dosing schedule, and the reasons are worth naming plainly. BPC-157 is not an approved drug, so there is no FDA label, no approved indication, and no titration guidance to quote [11]. The human evidence base — three small pilot studies — was never designed to find a dose-response curve; those studies tested feasibility and safety at a single fixed amount each [10][7]. A 2025 narrative review reading the same record concluded the compound should be treated as investigational and used with caution, in part because of that missing dose foundation [11]. Two further caveats shape how any figure should be read. A large share of the foundational animal work comes from a single research group, which newer authors note when discussing how settled the dose findings are [11]. And because BPC-157 is distributed largely through non-regulated channels, product identity, purity, and actual content are unverified outside formal studies [11] — so even the animal figures cannot be assumed to map onto unverified material. The result is a literature rich in per-kilogram animal data and silent on validated human dosing. ## How long should I stay on BPC-157? There is no established human dosing duration. BPC-157 is not an approved drug and there are no validated clinical protocols; published studies use species-specific animal regimens, which are not human guidance [11]. Questions of cycle length, frequency, and total duration sit entirely outside what the literature can answer for people, and this site does not supply them. --- A chalkboard reading of the BPC-157 research record — every figure chalked to its study, no clinic at the board and nothing here for sale.